EGFR and non-small cell lung carcinoma: In a randomized phase III RELAY study of ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced NSCLC, the results were published after primary analysis, performed separately in two sub-analyses for the East Asian and Europe/United States subsets (23, 33, 34).